John Smyth, MD, of the University of Edinburgh, discusses oncology from an international point of view.
Howard I. Scher, MD, of Memorial Sloan Kettering Cancer Center, discusses the updated criteria that will guide clinical trial design and conduct for therapeutics being tested in castration-resistant prostate cancer (Abstract 5000).
John L. Marshall, MD, of Georgetown University, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.
Lee S. Schwartzberg, MD, of The West Clinic, describes a new initiative of the Association of Community Cancer Centers, designed to speed the adoption of immunotherapeutics in the community setting, where 60% of cancer patients are treated.
Jedd Wolchok, MD, PhD, of Memorial Sloan Kettering Cancer Center discusses therapies for treatment-naive patients with advanced melanoma (Abstract LBA1).
Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Jedd Wolchok, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss therapies for treatment-naive patients with advanced melanoma (Abstract LBA1).
